Key Points
- Oruka Therapeutics insider Joana Goncalves sold 7,000 shares at an average price of $74.81, generating $523,670. The Rule 10b5-1 transaction reduced her direct ownership by 18.05% to 31,771 shares.
- ORKA shares opened at $73.87, below their 50-day moving average of $92.99 but within a 52-week range of $25.11 to $115.51. The company recently missed quarterly EPS expectations, reporting a loss of $0.55 versus the consensus loss of $0.51.
- Analysts remain broadly positive, with 10 Buy ratings and one Sell rating producing a “Moderate Buy” consensus and average price target of $128.91. Institutional investors own 56.44% of the stock, including a newly reported $26.5 million stake from Braidwell LP.
Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) insider Joana Goncalves sold 7,000 shares of the company's stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $74.81, for a total value of $523,670.00. Following the sale, the insider directly owned 31,771 shares in the company, valued at $2,376,788.51. This trade represents a 18.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Joana Goncalves also recently made the following trade(s):
- On Tuesday, September 15th, Joana Goncalves sold 7,947 shares of Oruka Therapeutics stock. The shares were sold at an average price of $92.38, for a total value of $734,143.86.
- On Monday, August 17th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $111.84, for a total transaction of $782,880.00.
Oruka Therapeutics Stock Performance
Shares of ORKA opened at $73.87 on Friday. The company's fifty day moving average is $92.99 and its 200 day moving average is $80.08. Oruka Therapeutics, Inc. has a fifty-two week low of $25.11 and a fifty-two week high of $115.51.
Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.04). As a group, sell-side analysts anticipate that Oruka Therapeutics, Inc. will post -2.42 earnings per share for the current year.
Institutional Trading of Oruka Therapeutics
Hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC boosted its stake in shares of Oruka Therapeutics by 201.6% during the third quarter. GAMMA Investing LLC now owns 374 shares of the company's stock valued at $31,000 after purchasing an additional 250 shares in the last quarter. Engineers Gate Manager LP bought a new stake in Oruka Therapeutics during the 2nd quarter valued at $350,000. Arizona State Retirement System increased its holdings in shares of Oruka Therapeutics by 45.0% in the 2nd quarter. Arizona State Retirement System now owns 8,671 shares of the company's stock valued at $825,000 after acquiring an additional 2,691 shares during the period. Nykredit A S bought a new stake in Oruka Therapeutics during the second quarter valued at about $29,000. Finally, Braidwell LP bought a new stake in Oruka Therapeutics during the second quarter valued at about $26,473,000. 56.44% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of brokerages have recently commented on ORKA. HC Wainwright reiterated a "buy" rating and issued a $120.00 target price on shares of Oruka Therapeutics in a report on Thursday, September 24th. BTIG Research restated a "buy" rating and issued a $151.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. UBS Group raised their target price on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the stock a "buy" rating in a report on Wednesday, July 1st. Piper Sandler reaffirmed an "overweight" rating on shares of Oruka Therapeutics in a research note on Wednesday, October 7th. Finally, Wedbush set a $120.00 target price on Oruka Therapeutics in a research report on Thursday, September 24th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $128.91.
View Our Latest Stock Analysis on ORKA
Oruka Therapeutics Company Profile
(
Get Free Report)
Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company's approach is designed to extend the duration of treatment and potentially reduce the frequency of dosing for patients with chronic inflammatory conditions.
Oruka's pipeline includes ORKA-001 and ORKA-002, next-generation monoclonal antibodies targeting interleukin-23 (IL-23), a cytokine involved in several autoimmune and inflammatory diseases.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
